Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The Vaso-Occlusive Pain Crisis in Sickle Cell Disease: Definition, Pathophysiology, and Management
source: European Journal of Haematology
year: 2020
authors: Deepika S. Darbari, Vivien A. Sheehan, Samir K. Ballas
summary/abstract:Early diagnosis, treatment, and prevention of a vaso-occlusive crisis (VOC) is critical to the management of patients with sickle cell disease. It is essential to differentiate between VOC-associated pain and chronic pain, hyperalgesia, neuropathy, and neuropathic pain. The pathophysiology of VOCs includes polymerization of abnormal sickle hemoglobin,inflammation, and adhesion.
Hydroxyurea, L-glutamine, crizanlizumab, and voxelotor have been approved by the US Food and Drug Administration for reducing the frequency of VOCs; the European Medicines Agency has approved only hydroxyurea. Other novel treatments are in late-stage clinical development in both the United States and the European Union. Development of agents for prevention and treatment of VOCs should be driven by our understanding of its pathophysiology.
organization: Children’s National Medical Center, USA; Baylor College of Medicine, USA; Thomas Jefferson University, USADOI: 10.1111/ejh.13430
read more
Related Content
-
The influence of the age of adults with sickle cell disease on the uptake, utilization and efficacy of HydroxyureaDespite the efficacy of Hydroxyurea (HU)...
-
Opioid utilization patterns in United States patients with sickle cell diseaseSickle cell disease (SCD) is the most co...
-
Testing Gene Editing for Sickle Cell Diseasehttps://www.youtube.com/watch?v=RGetNC2B...
-
Big Jump in Success for Sickle Cell TransplantsDoubling the dose of total-body irradiat...
-
A new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
-
Sickle Cell Foundation Nigeria, Rhieos Develop 1st Multi-SCD Registry in NigeriaIn a bid to improve quality of care for ...
-
Sickle Cell Disease Association of America, Inc. and Hemanext® Inc. Form New Strategic PartnershipSickle Cell Disease Association of Ameri...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
+myBinder